161 related articles for article (PubMed ID: 35793574)
21. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.
Wang S; Li M; Zhang J; Xing P; Wu M; Meng F; Jiang F; Wang J; Bao H; Huang J; Ren B; Yu M; Qiu N; Li H; Yuan F; Zhang Z; Jia H; Lu X; Zhang S; Wang X; Xu Y; Xia W; Liu T; Xu W; Xu X; Sun M; Wu X; Shao Y; Wang Q; Dai J; Qiu M; Wang J; Zhang Q; Xu L; Shen H; Yin R
J Hematol Oncol; 2022 Oct; 15(1):137. PubMed ID: 36183093
[TBL] [Abstract][Full Text] [Related]
22. Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.
Wang B; Pei J; Wang S; Cheng K; Yu J; Liu J
Crit Rev Oncol Hematol; 2022 Sep; 177():103771. PubMed ID: 35905822
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
24. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
25. The more potential performance of nidogen 2 methylation by tissue or plasma DNA over brichoalveolar lavage DNA in diagnosis of nonsmall cell lung cancer.
Feng X; Xie X; Zheng B; Peng C; Zhou H; Qin J
J Cancer Res Ther; 2018 Jun; 14(Supplement):S341-S346. PubMed ID: 29970687
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
Lu J; Feng Y; Guo K; Sun L; Ruan S; Zhang K
J Cancer Res Clin Oncol; 2024 Jan; 150(1):25. PubMed ID: 38252173
[TBL] [Abstract][Full Text] [Related]
27. DNA methylation markers and early recurrence in stage I lung cancer.
Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
[TBL] [Abstract][Full Text] [Related]
28. Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study.
Li M; Hou X; Zheng L; Ma Y; Li D; Lv Y; Chen J; Zheng W; Shao Y; Mou Y; Chen L
ESMO Open; 2022 Feb; 7(1):100305. PubMed ID: 34922300
[TBL] [Abstract][Full Text] [Related]
29. Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer Patients.
Ryu WK; Oh S; Lim JH; Lee SJ; Shin HT; Ryu JS
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076922
[TBL] [Abstract][Full Text] [Related]
30. Application of circulating tumor DNA for dynamic monitoring of advanced non-small cell lung cancer treatment response: An open-label, multicenter, prospective, observational study protocol.
Gao Z; Shang Y; Wang X; Ma Y; Yang F; Wang J; Chen K; Zhang Y
Thorac Cancer; 2019 May; 10(5):1310-1315. PubMed ID: 30980496
[TBL] [Abstract][Full Text] [Related]
31. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
[TBL] [Abstract][Full Text] [Related]
32. Early detection and stratification of lung cancer aided by a cost-effective assay targeting circulating tumor DNA (ctDNA) methylation.
Wang Z; Xie K; Zhu G; Ma C; Cheng C; Li Y; Xiao X; Li C; Tang J; Wang H; Su Z; Liu D; Zhang W; Huang Y; Tang H; Liu R; Li W
Respir Res; 2023 Jun; 24(1):163. PubMed ID: 37330511
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
Wislez M; Domblides C; Greillier L; Mazières J; Monnet I; Kiakouama-Maleka L; Quantin X; Spano JP; Ricordel C; Fraisse P; Janicot H; Audigier-Valette C; Amour E; Langlais A; Rabbe N; Makinson A; Cadranel J; Laurent-Puig P; Lavolé A; Blons H
Lung Cancer; 2021 Jul; 157():124-130. PubMed ID: 34016488
[TBL] [Abstract][Full Text] [Related]
34. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of circulating tumor DNA in localized non-small cell lung cancer: a systematic review and meta-analysis.
Guo RQ; Peng JZ; Sun J; Li YM
Clin Exp Med; 2023 Sep; 23(5):1621-1631. PubMed ID: 36315311
[TBL] [Abstract][Full Text] [Related]
36. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
[TBL] [Abstract][Full Text] [Related]
37. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
38. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
[TBL] [Abstract][Full Text] [Related]
39. Plasma cell-free DNA methylation combined with tumor mutation detection in prognostic prediction of patients with non-small cell lung cancer (NSCLC).
Guo D; Yang L; Yang J; Shi K
Medicine (Baltimore); 2020 Jun; 99(26):e20431. PubMed ID: 32590728
[TBL] [Abstract][Full Text] [Related]
40. A panel of promoter methylation markers for invasive and noninvasive early detection of NSCLC using a quantum dots-based FRET approach.
Ma Y; Bai Y; Mao H; Hong Q; Yang D; Zhang H; Liu F; Wu Z; Jin Q; Zhou H; Cao J; Zhao J; Zhong X; Mao H
Biosens Bioelectron; 2016 Nov; 85():641-648. PubMed ID: 27240011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
